TrovaGene (TROV) Releases Earnings Results, Beats Estimates By $0.05 EPS

TrovaGene (NASDAQ:TROV) announced its earnings results on Tuesday, May 7th. The medical research company reported ($1.02) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.07) by $0.05, Fidelity Earnings reports. The company had revenue of $0.16 million during the quarter. TrovaGene had a negative net margin of 3,540.91% and a negative return on equity of 121.65%.

TROV traded up $0.05 during trading on Friday, hitting $2.88. 53,187 shares of the company traded hands, compared to its average volume of 752,323. The firm has a market cap of $14.18 million, a P/E ratio of -0.35 and a beta of 0.74. The company has a debt-to-equity ratio of 0.16, a quick ratio of 3.76 and a current ratio of 3.76. TrovaGene has a one year low of $2.52 and a one year high of $20.16.

Several analysts have recently commented on the stock. Maxim Group set a $8.00 target price on shares of TrovaGene and gave the company a “buy” rating in a report on Thursday, May 23rd. Noble Financial set a $23.00 target price on shares of TrovaGene and gave the company a “buy” rating in a report on Friday, May 24th. Zacks Investment Research downgraded shares of TrovaGene from a “buy” rating to a “hold” rating in a report on Thursday, May 9th. Finally, ValuEngine downgraded shares of TrovaGene from a “buy” rating to a “hold” rating in a report on Wednesday, May 1st. Two research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $19.63.

COPYRIGHT VIOLATION WARNING: “TrovaGene (TROV) Releases Earnings Results, Beats Estimates By $0.05 EPS” was first published by Rockland Register and is the sole property of of Rockland Register. If you are reading this report on another domain, it was copied illegally and reposted in violation of US and international copyright laws. The correct version of this report can be accessed at https://rocklandregister.com/2019/05/31/trovagene-trov-releases-earnings-results.html.

TrovaGene Company Profile

Trovagene, Inc, a clinical-stage, precision medicine oncology therapeutics company, develops oncology therapeutics for cancer care by leveraging its proprietary Precision Cancer Monitoring (PCM) technology in tumor genomics. Its lead drug candidate, PCM-075, is a Polo-like Kinase 1 selective adenosine triphosphate competitive inhibitor.

Recommended Story: Risk Tolerance

Earnings History for TrovaGene (NASDAQ:TROV)

Receive News & Ratings for TrovaGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TrovaGene and related companies with MarketBeat.com's FREE daily email newsletter.